Medical
-
An article posted online in Thorax on January 14, 2013 finds that children and teens who eat three or more servings of fast food per week have a significantly increased risk of severe asthma. The… Read more . . .
-
Teva Respiratory says that the ProAir HFA metered dose inhaler with dose counter for the treatment of asthma is now available. The albuterol MDI with dose counter was approved by the FDA in March 2012.… Read more . . .
-
Matrixx Initiatives has voluntarily recalled a single lot of Zicam Extreme Congestion Relief nasal gel spray due to contamination with Burkholderia cepacia in a single sample. Zicam is a homeopathic product available over the counter… Read more . . .
-
Theravance has begun a dose ranging Phase 2b study of its TD-4208 inhalation solution in approximately 60 patients with moderate to severe COPD. According to the company, “The goal of Theravance’s LAMA program for respiratory… Read more . . .
-
A study by scientists from the UK Defence Science and Technology Laboratory (Dstl) showed that a single dose of Aradigm’s Lipoquin liposomal ciprofloxacin administered through the nose fully protected mice exposed to an aerosolized “lethal… Read more . . .
-
OptiNose has announced Phase 3 results from a study of its sumatriptan nasal powder for the treatment of migraine, as well as a grant from the Research Council of Norway to study nasal delivery of… Read more . . .
-
The FDA has issued a warning to parents and health care professionals after receiving reports of accidental ingestion of nasal sprays and eye drops by children. According to the agency, the decongestant nasal sprays reported… Read more . . .
-
According to Pearl Therapeutics, a randomized, double-blind, dose-ranging Phase 2b study of its PT003 formoterol fumarate (FF)/glycopyrrolate (GP) MDI for the treatment of moderate-to-severe COPD in more than a thousand patients showed that several doses… Read more . . .
-
According to Chiesi Group, a Phase 1 trial of its inhaled phosphodiesterase 4 (PDE4) inhibitor for the treatment of lung diseases such as COPD and asthma demonstrated that the drug, known as CHF 6001, was… Read more . . .
-
An article posted on October 4, 2012 on the BMJ publication Drug and Therapeutics Bulletin article asks, “who needs teaching?” when it comes to inhaler technique. The article points out that an overwhelming number of… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK

